216.73.216.231===--UPDATE `0-usmeigara` SET site='',name='',jigyoyoyaku='',sijyo='',gyosyu='',honten='',industry='',sector='',haishi='',keyword='' where code = 'dmk'---select * from `0-usmeigara` WHERE code='dmk'
aaＤＭＫファーマシューティカルズ

dmk
銘柄登録／業種登録　関連銘柄専用コメ／リスト／日本株
・

url
name
code
業種
htmldesc　分割：<split>
臨床段階の神経生物生物学企業であるDMK Pharmaceuticals Corporationは、アレルギー、オピオイドの過剰摂取、呼吸器、および炎症性疾患の治療分野で製品を開発および商業化します。同社のリード臨床段階製品候補であるDPI-125は、オピオイド使用障害の治療に適応されています。オピオイドの過剰摂取の治療のためのジミナロキソン注射。
keyword
sijyo
honten
industry
sector
haishi

事業内容も含めて検索

日本語に翻訳して１５０文字程度で要約を。語尾は「している」等の常体で
「DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California. On February 2, 2024, DMK Pharmaceuticals Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.」